The H-cadherin (CDH13) gene is inactivated in human lung cancer
- PMID: 9737784
- DOI: 10.1007/s004390050790
The H-cadherin (CDH13) gene is inactivated in human lung cancer
Erratum in
- Hum Genet 1998 Oct;103(4):532
Abstract
We have previously reported frequent allelic loss in chromosome bands 16q24.1-q24.2 in human lung cancer. Since the H-cadherin (CDH13) gene has been isolated and mapped to this common region of allelic loss, we have investigated this gene in human lung cancer. The reverse transcription/polymerase chain reaction technique has revealed the loss of expression in four (57%) of seven lung cancer cell lines. To study the CDH13 gene further, we have analyzed deletions, genetic alterations, and methylation status at the 5' region of this gene. Three (75%) of four cell lines that have lost expression show a deletion of the CDH13 locus accompanied by hypermethylation of the remaining allele. Moreover, hypermethylation has been observed in nine (45%) of 20 primary lung cancers. These results suggest that a combination of deletion and hypermethylation causes inactivation of the CDH13 gene in a considerable number of human lung cancers.
Similar articles
-
A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.PLoS One. 2016 May 6;11(5):e0149185. doi: 10.1371/journal.pone.0149185. eCollection 2016. PLoS One. 2016. PMID: 27153114 Free PMC article. Review.
-
Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.Cancer Res. 2001 Jun 1;61(11):4556-60. Cancer Res. 2001. PMID: 11389090
-
Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.Int J Oncol. 1999 Oct;15(4):715-20. doi: 10.3892/ijo.15.4.715. Int J Oncol. 1999. PMID: 10493953
-
Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas.Cancer Res. 2002 Jun 15;62(12):3382-6. Cancer Res. 2002. PMID: 12067979
-
Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma.Cancer. 2005 Nov 1;104(9):1825-33. doi: 10.1002/cncr.21409. Cancer. 2005. PMID: 16177988 Review.
Cited by
-
Maintaining the unmethylated state.Clin Epigenetics. 2013 Sep 30;5(1):17. doi: 10.1186/1868-7083-5-17. Clin Epigenetics. 2013. PMID: 24079333 Free PMC article.
-
Clinicopathological significance and potential drug target of T-cadherin in NSCLC.Drug Des Devel Ther. 2014 Dec 19;9:207-16. doi: 10.2147/DDDT.S74259. eCollection 2015. Drug Des Devel Ther. 2014. PMID: 25565774 Free PMC article.
-
A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.PLoS One. 2016 May 6;11(5):e0149185. doi: 10.1371/journal.pone.0149185. eCollection 2016. PLoS One. 2016. PMID: 27153114 Free PMC article. Review.
-
Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.Pathol Oncol Res. 2012 Jul;18(3):703-12. doi: 10.1007/s12253-012-9498-8. Epub 2012 Jan 26. Pathol Oncol Res. 2012. PMID: 22278416
-
DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma.PLoS One. 2011;6(6):e21443. doi: 10.1371/journal.pone.0021443. Epub 2011 Jun 23. PLoS One. 2011. PMID: 21731750 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous